PSPinar Siyah

Pinar Siyah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pinar Siyah has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Characterization of a Novel OTU-like Deubiquitinase from Neospora caninum and Discovery of Small-Molecule Inhibitors

    by Fatih Kocabaş, Sezer Akgöl, Pınar Siyah

    Neospora caninum is a major apicomplexan pathogen responsible for significant reproductive losses in livestock, yet lacks effective therapeutics. Here, we identify and functionally characterize a previously unstudied OTU-like deubiquitinase (ncOTU; XP_003886403) as a key modulator of host–pathogen interactions. Sequence and structural analyses revealed conservation of the catalytic triad (D257, C260, H362) and a Y305-W315-G316 inhibition pocket analogous to viral OTU proteases. Recombinant ncOTU exhibited robust deubiquitinase activity and significantly reduced global ubiquitination levels in mammalian cells, preferentially targeting mono-ubiquitinated and low-molecular-weight substrates. Transcriptomic analysis demonstrated that ncOTU expression correlates with suppressed NF-κB signaling, type I interferon responses, and downstream antiviral effectors, while partially uncoupling upstream nucleic acid sensing pathways. Structure-based virtual screening and biochemical validation identified multiple small-molecule inhibitors targeting the conserved inhibition pocket. Dose-response analysis revealed submicromolar potency for ncOTUi-9 (IC50 = 0.1 μM), ncOTUi-8 (0.2 μM), and ncOTUi-19 (0.3 μM), whereas ncOTUi-3 showed lower activity (7.1 μM). Interaction analyses confirmed stable binding within the inhibition pocket, with more extensive contact networks correlating with increased potency. Collectively, these findings establish ncOTU as a functional deubiquitinase that contributes to evasion and highlight it as a promising therapeutic target for neosporosis.

  • Open Access

    Synthesis and Development of Novel Small-Molecule MEIS2 Inhibitors That Induce Cell Death in Breast Cancer Cells by Targeting the Homeobox Domain

    by Fatih Kocabaş, Birkan Girgin, Merve Uslu, Pınar Siyah, Arif Mermer

    Background: MEIS proteins are essential homeobox transcription factors that play critical roles in development and have been increasingly implicated in oncogenesis, including breast cancer. Methods: In this study, we identified and characterized novel small-molecule MEIS2 inhibitors through in silico docking targeting the active region of the human MEIS2 homeobox domain. Lead candidates MEISi-2E, MEISi-3, and MEISi-4 were identified with binding energies ranging from −3.0 to −3.90 kcal/mol. The inhibitory potential of these molecules was validated in vitro using a species-conserved MEIS-Luciferase Reporter construct containing the TGACAG targeted locus. Results: Our results demonstrate that MEISi-2E, MEISi-3, and MEISi-4 significantly suppress MEIS-driven luciferase activity and downregulate the expression of Meis1, Meis2, and downstream genes such as IL17RB, CDH1, EGR2, PAX6, and SERPINE1 while upregulating negative regulator TGIF1 and SOX3. In breast cancer cell lines, these inhibitors exhibited potent growth inhibition, with MEISi-3 showing an exceptional IC50 as low as 0.1 μM in SK-BR-3 cells. Mechanistic studies using flow cytometry revealed that these inhibitors induce dose-dependent apoptosis and necrosis. Importantly, the novel inhibitors showed minimal toxicity to healthy human dermal and MRC5 fibroblasts, suggesting a favorable safety profile. Conclusions: These findings establish these small molecules as promising therapeutic candidates for targeting MEIS2-dependent pathways in breast cancer.

  • Advanced AI‐Driven in Silico Approaches for the Rapid Discovery of Potent BCL‐2 Inhibitors in Cancer Therapy

    by Pinar Siyah

    Cancer remains a leading cause of mortality worldwide, necessitating novel therapeutic approaches. This study utilized advanced in silico methods and artificial intelligence to identify new BCL‐2 inhibitors, a key apoptosis‐regulating protein often overexpressed in cancer cells. Machine learning‐based screening of 42 million Mcule compounds identified promising candidates, evaluated through molecular docking and dynamics simulations for BCL‐2 binding scores and stability. MetaCore/MetaDrug assessed drug‐likeness, QSAR predicted anticancer potential. Three promising molecules—Molecule #30, #73, and #75—were identified, consistently demonstrating superior or comparable binding scores to Venetoclax. For 1, 10, and 100 ns MD simulations, Molecule #30 scored −120.30, −122.02, and −122.68 kcal/mol; Molecule #73 scored −124.78, −125.62, and −125.42 kcal/mol; and Molecule #75 scored −120.02, −122.14, and −124.04 kcal/mol, respectively. Venetoclax, the reference drug, scored −100.66, −106.02, and −124.95 kcal/mol. These findings underscore the preclinical promise of these candidates, offering new opportunities for targeted cancer therapies and advancing oncology research.


  • Endoplasmic Reticulum Stress–Mediated Apoptosis Induced by Kaempferol in Colorectal Cancer Cells

    by Serdar Karakurt, Hatice Gül Batur, Kemal Bas, Pinar Siyah

    Due to its extended latency and high prevalence, human colorectal carcinoma (hCRC) represents an attractive candidate for dietary supplements that have shown remarkable success in tumor treatment. One natural dietary flavonoid, Kaempferol, exhibits numerous pharmacological activities, including antioxidant, antimicrobial, antidiabetic, and anticancer effects. This study aimed to investigate the anti‐proliferative effects of Kaempferol and clarify its molecular mechanism on hCRC. High‐pressure liquid chromatography (HPLC) and UV–Vis spectroscopy confirmed that the molecular structure of Kaempferol remained stable for up to 48 h. Confocal microscopy further demonstrated that Kaempferol localized in the cytoplasm of cells. The anticancer properties of Kaempferol were evaluated against several human cancer cell lines, including DLD‐1 (colorectal carcinoma), A549 (lung cancer), HUH‐7 (hepatocarcinoma), HeLa (cervical cancer), and NCI‐h295R (adrenal gland cancer), as well as the healthy epithelial cell line CCD‐18Co. Kaempferol significantly inhibited the proliferation of DLD‐1 cells, with an IC 50 value of 49.55 µM. Kaempferol treatment increased endoplasmic reticulum (ER) stress and apoptosis by 47% ( p < 0.001). Kaempferol also modulated the mRNA and protein expression of BcL‐2, Bax, Caspase‐3, Caspase‐9, Caspase‐12, Nf‐κB, p53, adenomatous polyposis coli (APC), MLH‐1, Smad‐4, XBP‐1, PERK, and ATF6. Molecular docking and 100 ns molecular dynamics simulations revealed a stable binding conformation of Kaempferol within the BcL‐2 active site, supported by key hydrogen bonds and hydrophobic interactions with residues such as Asn140 and Tyr199. MM/GBSA free energy and ligand efficiency calculations further confirmed its favorable binding characteristics. Collectively, these findings demonstrate that Kaempferol induces colorectal cancer cell death through ER stress–mediated apoptosis and BcL‐2 modulation, positioning it as a promising candidate for further preclinical development.


  • Targeting IL‐23 with Small Molecule Inhibitors: A New Horizon In Psoriasis Therapy

    by Raghad Sharbaji, Pinar Siyah

    Interleukin‐23 (IL‐23) is a dominant cytokine in psoriasis, a chronic inflammatory skin disease that severely diminishes patients' quality of life and reduces lifespan by up to 10 years. Despite therapeutic advancements, psoriasis remains a clinical challenge due to the absence of a definitive cure, treatment side effects, and substantial economic burden. Notably, no small molecule inhibitors (SMIs) directly targeting IL‐23 have been developed to date, leaving a critical gap in current therapies. In this study, SMIs emerged as promising therapeutic alternatives. A high‐throughput virtual screening of 1.57 million molecules was conducted, followed by molecular docking and molecular dynamics (MD) simulations (1, 10, and 100 ns) to identify potential candidates. Machine learning‐based binary QSAR models and MetaCore analysis established the relevance of these hits to psoriasis and other skin diseases. As a result, tenapanor (MM/GBSA score: −101.66 kcal/mol) and ChemBridge ID 7740 and ID 360118 (−101.59 kcal/mol, −91.003 kcal/mol) emerged as top candidates, demonstrating exceptional binding affinity and stability in 100‐ns simulations. These inhibitors represent promising therapeutic leads, offering an alternative to existing biologics. Further in vitro and in vivo validation will be essential to confirm their efficacy and potential as the first IL‐23‐targeted small molecule therapies.


  • In Silico Prediction of EGFR Inhibitors from Thiophene Derivatives

    by Pınar Siyah

    Cancer is one of the biggest global health problems and is the second leading cause of death worldwide. Cancer also causes great damage to economy. Unfortunately, there is still no effective treatment method against this disease today, and the mortality rates in certain types are still very high. Medical research can now be done faster and safer with the aid of in silico studies. These studies save time for researchers and accelerate new drug discoveries. In our study, thiophene derivatives with important efficacy in cancer treatment were focused on and the affinity of the small molecule structures determined as candidates to the Epidermal Growth Factor Receptor (EGFR), known to be the key receptor in cancer, was examined. First, molecular docking studies were performed, and then long-term molecular dynamics (MD) simulations were carried out. Finally, anti-cancer activity predictions based on Quantitative Structure-Activity Relationship (QSAR) were performed. Co-crystallized ligand Erlotinib, taken from the Protein Data Bank (PDB), was used as a positive control and compared with candidate drugs using the same procedures. In light of the analysis of virtual screening, MD, MM/GBSA, and QSAR predictions, the top three molecules and their MM/GBSA scores were identified as follows: OSI 930 (-65.81 kcal/mol), Neltenexine (-49.53 kcal/mol), and Tenonitrozole (-41.95 kcal/mol). As a result, in this study, candidate molecules that inhibit EGFR and have the highest potential as anti-cancer drugs among thiophene-derived compounds were determined and detailed in silico analyzes were performed. This study holds importance as it may guide future anti-cancer drug discovery studies.

  • Open Access

    Advanced Computational Pipeline for FAK Inhibitor Discovery: Combining Multiple Docking Methods with MD and QSAR for Cancer Therapy

    by Pinar Siyah

    Synthetic lethality, involving the simultaneous deactivation of two genes, disrupts cellular functions or induces cell death. This study examines its role in cancer, focusing on focal adhesion kinase and Neurofibromin 2. Inhibiting FAK, crucial for synthetic lethality with NF2/Merlin, offers significant cancer treatment potential. No FAK inhibitor has been clinically approved, underscoring the need for new, effective inhibitors. The small-molecule FAK inhibitors identified in this study show promise, with SP docking, IFD, QPLD, and MD simulations revealing intricate interactions. Based on the comprehensive analysis, the MM/GBSA scores from SP docking for amprenavir, bosutinib, ferric derisomaltose, flavin adenine dinucleotide, lactulose, and tafluprost were determined as −72.81, −71.84, −76.70, −69.09, −74.86, and −65.77 kcal/mol, respectively. The MMGBSA results following IFD docking MD identified the top-performing compounds with scores of −84.0518, −75.2591, −71.8943, −84.2638, −56.3019, and −75.3873 kcal/mol, respectively. The MMGBSA results from QPLD docking MD identified the leading compounds with scores of −77.8486, −69.5773, −71.9171, N/A, −62.5716, and −66.8067 kcal/mol, respectively. In conclusion, based on the MMGBSA scores obtained using the three docking methods and the 100 ns MD simulations, and considering the combined evaluation of these methods, amprenavir, ferric derisomaltose, and bosutinib are proposed as the most promising candidates.


  • Synthesis, in silico and bio-evaluation studies of new isothiocyanate derivatives with respect to COX inhibition and H 2 S release profiles

    by Yakup Berkay Yilmaz, Tuğba Güngör, Serhat Dönmez, Hazal Nazlıcan Atalay, Pınar Siyah, Serdar Durdağı, Mehmet Ay, Tugba Boyunegmez Tumer

    New isothiocyanate derivatives (I1–3 and I1a–e) were synthesized and screened for their anti-inflammatory activities and H 2 S-releasing capacities. Compounds I1 and I1c demonstrated the most potent and selective COX-2 inhibition.


  • Open Access

    The Potential Role of Boron in the Modulation of Gut Microbiota Composition: An In Vivo Pilot Study

    by Nermin Basak Sentürk, Burcu Kasapoglu, Eray Sahin, Orhan Ozcan, Mehmet Ozansoy, Muzaffer Beyza Ozansoy, Pinar Siyah, Ugur Sezerman, Fikrettin Sahin

    Background/Objectives: The role of the gut microbiome in the development and progression of many diseases has received increased attention in recent years. Boron, a trace mineral found in dietary sources, has attracted interest due to its unique electron depletion and coordination characteristics in chemistry, as well as its potential role in modulating the gut microbiota. This study investigates the effects of inorganic boron derivatives on the gut microbiota of mice. Methods: For three weeks, boric acid (BA), sodium pentaborate pentahydrate (NaB), and sodium perborate tetrahydrate (SPT) were dissolved (200 mg/kg each) in drinking water and administered to wild-type BALB/c mice. The composition of the gut microbiota was analyzed to determine the impact of these treatments. Results: The administration of BA significantly altered the composition of the gut microbiota, resulting in a rise in advantageous species such as Barnesiella and Alistipes. Additionally, there was a decrease in some taxa associated with inflammation and illness, such as Clostridium XIVb and Bilophila. Notable increases in genera like Treponema and Catellicoccus were observed, suggesting the potential of boron compounds to enrich microbial communities with unique metabolic functions. Conclusions: These findings indicate that boron compounds may have the potential to influence gut microbiota composition positively, offering potential prebiotic effects. Further research with additional analyses is necessary to fully understand the interaction between boron and microbiota and to explore the possibility of their use as prebiotic agents in clinical settings.